title: Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.
abstract: Activating mutations in the epidermal growth factor receptor (EGFR) have been identified in a subset of non-small cell lung cancer (NSCLC), which is one of the leading cancer types worldwide. Application of EGFR tyrosine kinase inhibitors leads to acquired resistance by secondary EGFR mutations or by amplification of the hepatocyte growth factor receptor (c-Met) gene. Although several EGFR and c-Met inhibitors have been reported, potent dual EGFR/c-Met inhibitors, which can overcome this latter resistance mechanism, have hitherto not been published and have not reached clinical trials. In the present study we have identified dual EGFR/c-Met inhibitors and designed novel N-[4-(quinolin-4-yloxy)-phenyl]-biarylsulfonamide derivatives, which inhibit the c-Met receptor and both the wild-type and the activating mutant EGFR kinases in nanomolar range. We have demonstrated by Western blot analysis that compound 10 inhibits EGFR and c-Met phosphorylation at cellular level and effectively inhibits viability of the NSCLC cell lines.
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary.
authors.forename: Bálint
authors.initials: B
authors.lastname: Szokol
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University , 1085 Budapest, Hungary.
authors.forename: Pál
authors.initials: P
authors.lastname: Gyulavári
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary.
authors.forename: Ibolya
authors.initials: I
authors.lastname: Kurkó
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary ; Rational Drug-Design Laboratory Cooperation Research Centre, Semmelweis University , 1085 Budapest, Hungary.
authors.forename: Ferenc
authors.initials: F
authors.lastname: Baska
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary.
authors.forename: Csaba
authors.initials: C
authors.lastname: Szántai-Kis
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Greff
authors.affiliation: Rational Drug-Design Laboratory Cooperation Research Centre, Semmelweis University , 1085 Budapest, Hungary ; Max Planck Institute of Biochemistry , Munich 82152, Germany.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Orfi
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University , 1085 Budapest, Hungary ; KPS Medical Biotechnology and Healthcare Services Ltd. , 1022 Budapest, Hungary.
authors.forename: István
authors.initials: I
authors.lastname: Peták
authors.affiliation: Max Planck Institute of Biochemistry , Munich 82152, Germany.
authors.forename: Kinga
authors.initials: K
authors.lastname: Pénzes
authors.affiliation: Max Planck Institute of Biochemistry , Munich 82152, Germany.
authors.forename: Robert
authors.initials: R
authors.lastname: Torka
authors.affiliation: Max Planck Institute of Biochemistry , Munich 82152, Germany.
authors.forename: Axel
authors.initials: A
authors.lastname: Ullrich
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary ; Department of Pharmaceutical Chemistry, Semmelweis University , 1085 Budapest, Hungary.
authors.forename: László
authors.initials: L
authors.lastname: Orfi
authors.affiliation: MTA-SE Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University , 1085 Budapest, Hungary.
authors.forename: Tibor
authors.initials: T
authors.lastname: Vántus
authors.affiliation: Vichem Chemie Research Ltd. , 1022 Budapest, Hungary ; MTA-SE Pathobiochemistry Research Group, Department of Medical Chemistry, Semmelweis University , 1085 Budapest, Hungary ; Rational Drug-Design Laboratory Cooperation Research Centre, Semmelweis University , 1085 Budapest, Hungary.
authors.forename: György
authors.initials: G
authors.lastname: Kéri
keywords: EGFR; NSCLC; acquired resistance; c-Met; kinase inhibitor